Bayer AG

BAYN

DE000BAY0017

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Employees

96,567

Sector

Pharmaceuticals

Calendar

05/11/2024 - Q3 2024 Earnings Release

Related indices

Euro STOXX 50 Index , STOXX Europe 600 Index (EUR) , DAX

More about the company

Income Statement and Estimates

More financial data

Analysis / Opinion

BAYER : Crop Science’s weaker 2024

August 19, 2024 at 12:10 pm

Bayer AG: Not out of the woods yet

March 06, 2024 at 03:46 pm

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

27.01EUR

Average target price

35.59EUR

Spread / Average Target

+31.77%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Real-time Estimate Tradegate Other stock markets 13:43:29 12/09/2024 BST			5-day change	1st Jan Change
27.00 ^EUR	-0.04%		-6.54%	-19.48%

09:53am	Bayer wins another glyphosate lawsuit in the USA	DP
09:33am	Bayer's Monsanto Secures Favorable Verdict in Roundup Weedkiller Philadelphia Trial	MT

Bayer wins another glyphosate lawsuit in the USA	08:53am	DP
Bayer's Monsanto Secures Favorable Verdict in Roundup Weedkiller Philadelphia Trial	08:33am	MT
Jury rules in favor of Bayer's Monsanto in Philadelphia trial over Roundup	02:58am	RE
Bayer to present results from AMD trials	09-11	CF
Agrochemicals group Syngenta cuts jobs in Basel	09-11	RE
Bayer falls in recovered market environment - glyphosate remains in focus	09-11	DP
Bayer wants to take glyphosate lawsuits to the highest US court	09-11	RE
Goldman rates Bayer at 'Neutral' - Target 30 euros	09-10	DP
BAYER AG : Goldman Sachs remains Neutral	09-10	ZD
Study: Agriculture could significantly reduce greenhouse gases	09-10	DP
Bayer's Finerenone Cuts Risk of New-onset Diabetes in Late-stage Trial	09-10	MT
Bayer's OcuClick Secures Approval from European Medicines Agency	09-09	MT
BAYER AG : UBS sticks Neutral	09-09	ZD
Bayer: receives EMA approval	09-09	CF
Bayer: last-minute presentations at ESMO congress	09-06	CF
Veeva Systems: leader in cloud solutions for the life sciences industry	09-06
Bayer's bottoming out continues to take shape - BofA commentary	09-06	DP
Bayer gains significantly - focus on US glyphosate dispute	09-05	DP
Bayer: new data for menopause treatment	09-05	CF
Bayer: will present new data at ESMO	09-05	CF
WDH: Fewer crop protection products planned for fields	09-04	DP
Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause	09-04	CI
Expert dialog recommends restructuring EU agricultural policy	09-04	DP
Transcript : Bayer Aktiengesellschaft Presents at Barclays 17th Annual Global Consumer Staples Conference, Sep-03-2024 04:29 PM	09-03
Bayer: FDA approval for investigational drug	09-03	CF

Bayer AG

Equities